Search Results - "JACQMIN, P"

Evidence of NI‐0101 pharmacological activity, an anti‐TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS by Monnet, E, Lapeyre, G, Poelgeest, E van, Jacqmin, P, Graaf, K de, Reijers, J, Moerland, M, Burggraaf, J, Min, C de

“…Toll‐like receptor‐4 (TLR4) pathways are major contributors to pathological inflammatory responses induced by tissue damage. NI‐0101 is the first monoclonal…”
Get full text

On Fibrations Between Internal Groupoids and Their Normalizations by Jacqmin, P.-A., Mantovani, S., Metere, G., Vitale, E. M.

“…We characterize fibrations and ∗ -fibrations in the 2-category of internal groupoids in terms of the comparison functor from certain pullbacks to the…”
Get full text

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure by Snoeck, E, Chanu, P, Lavielle, M, Jacqmin, P, Jonsson, E N, Jorga, K, Goggin, T, Grippo, J, Jumbe, N L, Frey, N

“…We propose a model that characterizes and links the complexity and diversity of clinically observed hepatitis C viral kinetics to sustained virologic response…”
Get full text

Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR‐SOB Scores From ADNI by Delor, I, Charoin, J‐E, Gieschke, R, Retout, S, Jacqmin, P

“…Disease‐onset time (DOT) and disease trajectory concepts were applied to derive an Alzheimer's disease (AD) progression population model using the clinical…”
Get full text

Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model by Jacqmin, P, Snoeck, E, van Schaick, E A, Gieschke, R, Pillai, P, Steimer, J-L, Girard, P

“…The plasma concentration-time profile of a drug is essential to explain the relationship between the administered dose and the kinetics of drug action…”
Get full text

Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment‐Experienced HIV‐1–Infected Patients in the MOTIVATE Studies by Jacqmin, P, Wade, JR, Weatherley, B, Snoeck, E, Marshall, S, McFadyen, L

“…Efficacy exposure–response relationships of the CCR5 antagonist maraviroc were evaluated across two phase III clinical trials. This post‐hoc analysis used…”
Get full text

Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis by Locatelli, Franco, Jordan, Michael B, Allen, Carl, Cesaro, Simone, Rizzari, Carmelo, Rao, Anupama, Degar, Barbara, Garrington, Timothy P, Sevilla, Julian, Putti, Maria-Caterina, Fagioli, Franca, Ahlmann, Martina, Dapena Diaz, Jose-Luis, Henry, Michael, De Benedetti, Fabrizio, Grom, Alexei, Lapeyre, Genevieve, Jacqmin, Philippe, Ballabio, Maria, de Min, Cristina

“…Primary hemophagocytic lymphohistiocytosis, a rare genetic immune disorder characterized by hyperinflammation, manifests in infancy and is associated with high…”
Get full text

SC-54684A : an orally active inhibitor of platelet aggregation by NICHOLSON, N. S, PANZER-KNODLE, S. G, ENGLEMAN, V. W, HERIN, M, JACQMIN, P, FEIGEN, L. P, SALYERS, A. K, TAITE, B. B, SZALONY, J. A, HAAS, N. F, KING, L. W, ZABLOCKI, J. A, KELLER, B. T, BROSCHAT, K

“…Intravenous therapy has been shown to be beneficial in the prevention of acute platelet-associated thrombotic events. However, orally active agents would be…”
Get full text

The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine by SNOECK, E, JACQMIN, P, HEYKANTS, J, VAN PEER, A, DANHOF, M, VER DONCK, K, VAN BELLE, H, WOESTENBORGHS, R, CRABBE, R, VAN GOOL, R, DUPONT, A

“…1. Draflazine, a nucleoside transport inhibitor, was administered as a 15 min i.v. infusion of 2.5 mg to eight healthy male subjects. Plasma and whole blood…”
Get full text

PF246 PERSONALIZED FOLLOW‐UP OF ACUTE MYELOID LEUKEMIA THROUGH MULTIPARAMETER FLOW CYTOMETRY: A PROOF OF CONCEPT by Jacqmin, H., Louveaux, Q., Chatelain, B., Jacqmin, P., Chatelain, C., Dogné, J.‐M., Graux, C., Mullier, F.

“…Background: Standardization, machine learning techniques and comparison to normality are concepts that are changing the landscape of multiparameter flow…”
Get full text

Commentary on "Hydroxypropyl cyclodextrins: potential synergism with carcinogens" by Van Cauteren, H, Jacqmin, P, Coussement, W, Meuldermans, W, Lampo, A, Lammens, L

Get more information

Population analysis of the non linear red blood cell partitioning and the concentration‐effect relationship of draflazine following various infusion rates by Snoeck, E., Piotrovskij, V., Jacqmin, P., Van Peer, A., Danhof, M., Ver Donck, K., Woestenborghs, R., Van Belle, H., Van Bortel, L., Van Gool, R., Dupont, A. G., Heykants, J.

“…Aims To investigate the impact of the specific red blood cell binding on the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor…”
Get full text

A study of lactate metabolism without tracer during passive and active postexercise recovery in humans by Francaux, M, Jacqmin, P, de Welle, J M, Sturbois, X

“…Tracers have been used extensively to study lactate metabolism in humans during rest and exercise. Nevertheless, quantification of in vivo lactate kinetics as…”
Get full text

The maximum lactate clearance: a new concept to approach the endurance level of an athlete by Francaux, M A, Jacqmin, P A, Sturbois, X G

“…The purpose of this study is to present a mathematical model based on physiological observations which describes the evolution of the blood lactate…”
Get more information

Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations by SNOECK, E, PIOTROVSKIJ, V, JACQMIN, P, LINS, R. L, VAN PEER, A, DANHOF, M, WOESTENBORGHS, R, VAN GOOL, R, DUPONT, A. G, HEYKANTS, J

“…The pharmacokinetics and non-linear red blood cell partitioning of the nucleoside transport inhibitor draflazine were investigated in 19 healthy male and…”
Get full text

Variations in lactate apparent clearance during rest and exercise in normal man by Francaux, M A, Jacqmin, P A, Sturbois, X G

“…The purpose of this study is to present a simple kinetic model for the study of the lactate metabolism. This model based on pharmacokinetic theory, does not…”
Get more information

Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data by Jacqmin, P, Ansseau, M

“…The pharmacokinetic profiles of oral and sublingual administrations of prazepam 20 mg to 5 normal volunteers were compared in order to explain the clinical…”
Get more information

A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis by Pillai, Goonaseelan, Gieschke, Ronald, Goggin, Timothy, Jacqmin, Philippe, Schimmer, Ralph C., Steimer, Jean‐Louis

“…Aims Ibandronate, a highly potent nitrogen‐containing bisphosphonate, is the subject of an ongoing clinical development programme that aims to maximize the…”
Get full text

A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc by Rosario, Maria C., Jacqmin, Philippe, Dorr, Pat, Ryst, Elna, Hitchcock, Chris

“…Background The viral dynamics of human immunodeficiency virus (HIV) infection has been widely studied and expressed as mathematic equations. For most of the…”
Get full text

Irreversible binding to proteins after single and repeated daily oral administration of 4-(2,2-diphenylethyl) imidazole (SC-46264) to the Cynomolgus monkey by JACQMIN, P, HERIN, M, CAVALIER, R, LESNE, M

“…SC-46264 is an antagonist of the alpha 2-adrenergic receptor. Distribution and excretion of [14C]-SC-46264 were studied after single and repeated daily oral…”
Get full text